Company Description
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients.
The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products.
It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International.
Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
| Country | Ireland |
| Founded | 1987 |
| IPO Date | Jul 16, 1991 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 2,050 |
| CEO | Richard Pops |
Contact Details
Address: Connaught House, 1 Burlington Road Dublin, D04 C5Y6 Ireland | |
| Phone | 353 1 772 8000 |
| Website | alkermes.com |
Stock Details
| Ticker Symbol | ALKS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001520262 |
| CUSIP Number | G01767105 |
| ISIN Number | IE00B56GVS15 |
| Employer ID | 98-1007018 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard F. Pops | Chairman and Chief Executive Officer |
| Blair C. Jackson | Executive Vice President, Chief Risk Officer and Chief Operating Officer |
| David Joseph Gaffin J.D. | Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary |
| Dr. Craig C. Hopkinson M.D. | Executive Vice President of Research and Development and Chief Medical Officer |
| Christian Todd Nichols | Senior Vice President and Chief Commercial Officer |
| Joshua Reed M.B.A. | Senior Vice President and Chief Financial Officer |
| Samuel J. Parisi | Interim Principal Accounting Officer and Vice President of Finance |
| Thomas Harvey | Chief Information Officer and Senior Vice President of IT |
| Sandra Coombs | Senior Vice President of Corporate Affairs and Investor Relations |
| Stephen Schiavo | Senior Vice President and Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 3, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Feb 25, 2026 | 8-K | Current Report |
| Feb 25, 2026 | 10-K | Annual Report |
| Feb 25, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G | Filing |
| Feb 12, 2026 | 8-K | Current Report |
| Feb 2, 2026 | 144 | Filing |